Good news on the efficacy of the “Pfizer” vaccine against the mutated Corona strain

British Health has announced good news regarding the effectiveness of Pfizer’s vaccine against the mutated South African strain.

The number of Covid-19 vaccines is expected to increase, as Johnson & Johnson and Novavax announced positive results for their vaccines last week.

Neither method appears to be as effective as the first vaccines using a new technology called messenger RNA – one from Pfizer and its partner Biontech, and the other from Moderna, prevented around 95% of symptom cases, while that the efficacy of the new vaccines was 89% for the Novavax vaccine, 66% Johnson.

All four vaccines, in addition to the unavailable U.S. vaccines from AstraZeneca, and those from China and Russia, have exceeded the 50% efficacy level set by U.S. regulators to obtain production approval, according to Bloomberg, and seen by Al Arabiya .net.

Vaccines pose obstacles, of varying heights, preventing the virus from controlling a potential new victim. And if vaccines can prevent a sufficiently widespread spread, it will be difficult for the virus to compete, and ultimately it will be out of the race.

And with the virus spreading less, there will be less risk of exposure for everyone, whether they receive the strongest or the least potent vaccines or not at all.

The good news about Johnson & Johnson and Novavax vaccines is that they are easy to distribute. Since they do not need to be severely frozen during transport, the Johnson & Johnson vaccine works with a single dose. Both companies are committed to producing millions of doses for the world in the coming months.